Abstract
Mycobacterium bovis bacillus Calmette–Guérin (BCG) is the only live attenuated vaccine available against tuberculosis. The first BCG vaccination was done exactly 100 years ago, in 1921. The BCG vaccine strains used worldwide represent a family of daughter sub-strains with distinct genotypic characteristics. BCG SL222 Sofia is a seed lot sub-strain descending from the Russian BCG-I (seed lot 374a) strain and has been used for vaccine production in Bulgaria since 1972. Here, we report the assembled circular genome sequence of Mycobacterium bovis BCG SL222 Sofia and phylogeny analysis with the most closely related BCG sub-strains. The full circular genome of BCG SL222 Sofia had a length of 4,370,706 bp with an average GC content of 65.60%. After 49 years of in vitro evolution in a freeze-dried condition, we identified four SNP mutations as compared to the reference BCG-I (Russia-368) sequence. BCG vaccination is of central importance for the TB elimination programs in many countries. Since 1991, almost 40 million vaccine doses of the BCG SL222 Sofia have been distributed annually through the United Nations Children’s Fund (UNICEF) and the Pan American Health Organization (PAHO) to approximately 120 countries. The availability of the complete reference genome sequence for M. bovis BCG SL222 Sofia, a WHO reference reagent for the Russian BCG-I sub-strain, will facilitate the identity assurance of the genomic stability, will contribute to more consistent manufacturing, and has an important value in standardization and differentiation of sub-strains used in vaccine production. We propose to rename the sub-strain BCG SL222 Sofia to BCG-Sofia for practical and common use.
Highlights
The bacillus Calmette–Guérin (BCG) vaccine sub-strains currently in use are all progenies of the original strain attenuated by Calmette and Guérin during 1908–1921 [1]
Complete genome sequencing of mycobacteria and BCG sub-strains is challenged by the occurrence of large genome segments of a variable number of tandem repeats (VNTR)
BCG vaccination will continue to play a major role in TB control worldwide
Summary
The BCG vaccine sub-strains currently in use are all progenies of the original strain attenuated by Calmette and Guérin during 1908–1921 [1]. Among the family of BCG sub-strains unique molecular profiles were detected [2,3]. This fact suggests ongoing in vitro microevolution of the BCG sub-strains that started in 1908. After a century of mass use, BCG vaccine demonstrated a duration of protection of at least ten years with residual vaccine effectiveness up to 20–25 years [4]. Five WHO reference BCG vaccine preparations, namely Danish
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.